

## References

### I-161

1. Chang T, Shiah H, Yang C, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. *Cancer Chemother and Pharmacol.* 2015;75(3):579-586.
2. Koeller J, Surinach A, Arikian S.R, et al. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. *Ther Adv Med Oncol.* 2020:12.
3. Wang-Gillam A, Hubner RA, Siveke, JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. *Eur J Cancer.* 2019;108:78-87.
4. Yoo C, Kim KP, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): A multicentre, open-label, randomised, phase 2b study. *Lancet Oncol.* 2021;22:1560–72.
5. Irinotecan In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 3, 2017.
6. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Irinotecan Liposomal.
7. Micromedex DrugDex Compendium®. 2024. Irinotecan Liposome (Onivyde).
8. National Comprehensive Cancer Network (NCCN). Onivyde. NCCN Drugs and Biologics Compendium®. 2024.
9. Onivyde (irinotecan liposome injection) for intravenous use [package insert]. Ipsen Biopharmaceuticals, Inc. Basking Ridge, NJ. Revised 02/2024.